An AI platform that matches eligible patients with clinical trials by analyzing medical data, cutting recruitment time by 40% and addressing a major bottleneck in biotech research.
TrialMatch leverages advanced AI to de-identify and analyze medical records, creating a secure bridge between pharmaceutical researchers and eligible patients. This platform directly tackles the critical and costly challenge of patient recruitment, which often delays life-saving treatments and consumes up to 30% of a trial’s budget. By automating eligibility screening and streamlining consent, it promises to accelerate the entire drug development pipeline.
Core functionality
TrialMatch’s core is an AI engine that processes de-identified medical records and patient registry data. It automates the initial eligibility screening against complex trial protocols. The platform features a secure researcher dashboard for managing recruitment campaigns and a patient portal for consent management and communication, all built on a HIPAA/GDPR-compliant foundation.
Target user and segment
The primary users are pharmaceutical researchers and Clinical Research Organizations (CROs). The secondary users are patients seeking trial opportunities. The initial focus is on therapeutic areas with the most complex recruitment challenges: oncology, rare diseases, and chronic conditions.
Recommended tech stack
- Backend: Python (TensorFlow/PyTorch), Node.js
- Frontend: React.js
- Database: PostgreSQL (structured data), MongoDB (unstructured medical data)
- Infrastructure: HIPAA-compliant AWS hosting
- Integration: FHIR API for EHR connectivity
- Security: Optional blockchain layer for immutable consent tracking
Estimated MVP hours and costs
Total MVP Development: 1,200 hours
Hourly Rate: €100
Total Cost: €120,000
Breakdown:
- AI Model Development: 400h (€40,000)
- Secure Data Pipeline: 300h (€30,000)
- Frontend/Backend Development: 350h (€35,000)
- Compliance & Security: 150h (€15,000)
SWOT-analysis
Strengths: First-mover in AI-driven matching, addresses a massive pain point, strong pharma partnership potential.
Weaknesses: Significant regulatory hurdles (HIPAA/GDPR), challenging data acquisition, high initial customer acquisition cost.
Opportunities: Growing €44B EU clinical trial market, regulatory push for digital endpoints, integration with telehealth.
Threats: Competition from established players (e.g., Medable, Science 37), hospital data silos, ethical concerns over data usage.
First 1000 customers strategy
Acquisition Channels:
- Direct B2B Sales to Top 20 Pharma: 60%
- Medical Conference Partnerships: 20%
- Physician Referral Programs: 15%
- Patient Advocacy Groups: 5%
Costs & Targets: Target 100 enterprise clients (research teams) and 900 patient users in Year 1. Estimated acquisition cost of €250-500 per enterprise client and €50-100 per patient.
Monetization
Business Model: Dual-stream SaaS. Researchers: €5,000-15,000/month subscription (based on trial size). Success Fee: €500-2,000 per successfully enrolled patient. Patient access is free.
Break-even analysis: Break-even requires 15 enterprise clients or 100 patient enrollments per month. Projected ARR of €1.2M is achievable with 20 clients and 200 enrollments/month.
Core personnel estimations: Initial team of 6: CEO (€120k), CTO (€110k), 2 AI Engineers (€180k), Compliance Officer (€100k), Sales Lead (€90k + commission). Total annual personnel cost: ~€600k.
Market positioning and competitors
Regional Market Size: The EU clinical trial market is valued at €8.3B, with patient recruitment representing 20-30% of total trial costs.
Competitors: Contrast with traditional CROs (IQVIA, PPD) and digital platforms (Medable, Science 37) which focus more on decentralized trial execution than AI-powered pre-screening and matching.
Sales Strategy: Land-and-expand strategy targeting the top 10 pharma companies. Leverage principal investigators as champions and build a case study library highlighting the 40% recruitment time reduction.
Market Niche: Own the niche of AI-first recruitment specifically for complex therapeutic areas where narrow eligibility criteria make finding patients most difficult and costly.
